Recorded Chinese product: 注射用亚叶酸钙注射用亚叶酸钙
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 上海华联制药有限公司Chinese legal name: 上海华联制药有限公司
主要成分Active Ingredients
- 亚叶酸钙CF
药物知识说明
亚叶酸钙是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括:亚叶酸钙Yaye Suangai。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品:亚叶酸钙-8f402481成分药品。
本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 注射用亚叶酸钙) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Active ingredients associated with this product: 亚叶酸钙Yaye Suangai.
Explore other medicines containing the same ingredient: 亚叶酸钙 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 注射用亚叶酸钙Recorded Chinese product: 注射用亚叶酸钙
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 100mg100 mg
本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 上海华联制药有限公司Chinese legal name: 上海华联制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H31021669
关联实体Relationships
信息来源Source and scope
国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H31021669
Manufacturer
Chinese legal name: 上海华联制药有限公司
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H31021669
生产企业
上海华联制药有限公司
适应症
主要用作叶酸拮抗剂(如甲氨蝶呤、乙胺嘧啶或甲氧苄啶等)的解毒剂。本品临床常用于预防甲氨蝶呤过量或大剂量治疗后所引起的严重毒性作用。当口服叶酸疗效不佳时,也用于口炎性腹泻、营养不良、妊娠期或婴儿期引起的巨幼细胞性贫血,但对维生素B12缺乏性贫血并不适用。近年应用亚叶酸钙作为结肠、直肠癌的辅助治疗,与氟尿嘧啶联合应用,可延长存活期。
用法用量
规定的剂量和给药时间均应严格遵守,不得随意改变。补加剂量或停药必须经负责医师同意。肌内注射:作为甲氨蝶呤的“解救”疗法,本品剂量最好根据血药浓度测定。一般采用剂量按体表面积为9-15mg/m2,每6-8小时一次,持续2日,直至甲氨蝶呤血清浓度在5×10-8mol/L以下。作为乙胺嘧啶或甲氧苄啶等的解毒剂,每次剂量肌注9-15mg,视中毒情况而定。用于贫血,每日肌注1mg。静脉注射:作为结肠一直肠癌的辅助治疗,与氟尿嘧啶联合应用;本品静脉注射200mg/m2,注射时间不少于3分钟,接着用氟尿嘧啶300-400mg/m2静脉注射,每日一次,连续5日为一疗程,根据毒性反应,每隔4-5周可重复一次,以延长存活期。小儿剂量可酌情参照成人用量。
不良反应
很少见,偶见皮疹、荨麻疹或引起哮喘急性发作等。
禁忌
尚不明确。
贮藏
避光,密闭保存。
规格
100mg
信息来源Source and scope
国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.